Teldy (Dolutegravir + Lamivudine + Tenofovir)

TELDY (Dolutegravir + Lamivudine + Tenofovir) is a once-daily, single-pill antiretroviral therapy (ART) combining three potent HIV medications in fixed-dose combination. This FDA/DOH/WHO-recommended first-line treatment is designed for adults and adolescents weighing at least 40 kg seeking effective viral suppression and immune protection.

Each tablet delivers Dolutegravir 50 mg, Lamivudine 300 mg, and Tenofovir disoproxil fumarate 300 mg—three complementary agents that work synergistically to inhibit HIV replication at multiple stages. Dolutegravir, an integrase strand transfer inhibitor, prevents viral DNA integration. Lamivudine and Tenofovir, both nucleoside reverse transcriptase inhibitors, block reverse transcriptase activity. Together, they reduce viral load to undetectable levels, preserving CD4 count and enabling immune system recovery.

TELDY is taken once daily with or without food, improving adherence and treatment outcomes. Common side effects may include insomnia or mood changes—taking the dose in the morning can minimize these effects. Avoid concurrent use with calcium, magnesium, or aluminum-containing antacids, as they reduce drug absorption.

As a cost-effective generic formulation, TELDY is widely accessible across low and middle-income countries, including the Philippines, making it a practical option for sustained HIV management. Patent restrictions limit availability in high-income markets, but international procurement remains possible through authorized distributors.

TELDY represents a durable, simplified regimen with proven efficacy, tolerability, and real-world effectiveness in diverse patient populations globally.